Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-048957
Filing Date
2026-02-12
Accepted
2026-02-12 16:59:04
Documents
101
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K crsp-20251231.htm   iXBRL 10-K 4461993
2 EX-4.1 crsp-ex4_1.htm EX-4.1 28091
3 EX-21.1 crsp-ex21_1.htm EX-21.1 7783
4 EX-23.1 crsp-ex23_1.htm EX-23.1 7886
5 EX-31.1 crsp-ex31_1.htm EX-31.1 14202
6 EX-31.2 crsp-ex31_2.htm EX-31.2 14176
7 EX-32.1 crsp-ex32_1.htm EX-32.1 13533
8 GRAPHIC img88010708_0.jpg GRAPHIC 272537
9 GRAPHIC img88010708_1.jpg GRAPHIC 733899
10 GRAPHIC img88010708_2.jpg GRAPHIC 485395
11 GRAPHIC img88010708_3.jpg GRAPHIC 336661
12 GRAPHIC img88010708_4.jpg GRAPHIC 553881
13 GRAPHIC img88010708_5.jpg GRAPHIC 460653
14 GRAPHIC img88010708_6.jpg GRAPHIC 505014
  Complete submission text file 0001193125-26-048957.txt   24441834

Data Files

Seq Description Document Type Size
15 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20251231.xsd EX-101.SCH 1785430
104 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20251231_htm.xml XML 3392572
Mailing Address BAARERSTRASSE 14 ZUG Switzerland
Business Address BAARERSTRASSE 14 ZUG Switzerland 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37923 | Film No.: 26627374
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)